Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
Status:
Withdrawn
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of guadecitabine when given
together with nivolumab and to see how well they work in treating participants with
colorectal cancer that does not respond to treatment and has spread to other places in the
body. Drugs used in chemotherapy, such as guadecitabine, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with
the ability of tumor cells to grow and spread. Giving guadecitabine and nivolumab may work
better in treating participants with colorectal cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Southern California
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Bristol-Myers Squibb National Cancer Institute (NCI)